JP2020504112A5 - - Google Patents

Download PDF

Info

Publication number
JP2020504112A5
JP2020504112A5 JP2019533594A JP2019533594A JP2020504112A5 JP 2020504112 A5 JP2020504112 A5 JP 2020504112A5 JP 2019533594 A JP2019533594 A JP 2019533594A JP 2019533594 A JP2019533594 A JP 2019533594A JP 2020504112 A5 JP2020504112 A5 JP 2020504112A5
Authority
JP
Japan
Prior art keywords
seq
fab
variable region
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019533594A
Other languages
English (en)
Japanese (ja)
Other versions
JP7181203B2 (ja
JP2020504112A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/058159 external-priority patent/WO2018116178A1/en
Publication of JP2020504112A publication Critical patent/JP2020504112A/ja
Publication of JP2020504112A5 publication Critical patent/JP2020504112A5/ja
Priority to JP2022167563A priority Critical patent/JP7622017B2/ja
Application granted granted Critical
Publication of JP7181203B2 publication Critical patent/JP7181203B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019533594A 2016-12-21 2017-12-19 造血幹細胞を除去するための抗体薬物結合体 Active JP7181203B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022167563A JP7622017B2 (ja) 2016-12-21 2022-10-19 造血幹細胞を除去するための抗体薬物結合体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662437622P 2016-12-21 2016-12-21
US62/437,622 2016-12-21
US201762520854P 2017-06-16 2017-06-16
US62/520,854 2017-06-16
PCT/IB2017/058159 WO2018116178A1 (en) 2016-12-21 2017-12-19 Antibody drug conjugates for ablating hematopoietic stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022167563A Division JP7622017B2 (ja) 2016-12-21 2022-10-19 造血幹細胞を除去するための抗体薬物結合体

Publications (3)

Publication Number Publication Date
JP2020504112A JP2020504112A (ja) 2020-02-06
JP2020504112A5 true JP2020504112A5 (https=) 2021-02-04
JP7181203B2 JP7181203B2 (ja) 2022-11-30

Family

ID=60957364

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019533594A Active JP7181203B2 (ja) 2016-12-21 2017-12-19 造血幹細胞を除去するための抗体薬物結合体
JP2022167563A Active JP7622017B2 (ja) 2016-12-21 2022-10-19 造血幹細胞を除去するための抗体薬物結合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022167563A Active JP7622017B2 (ja) 2016-12-21 2022-10-19 造血幹細胞を除去するための抗体薬物結合体

Country Status (24)

Country Link
US (3) US11357864B2 (https=)
EP (1) EP3558389A1 (https=)
JP (2) JP7181203B2 (https=)
KR (2) KR20240093751A (https=)
CN (2) CN117653740A (https=)
AU (1) AU2017383458C1 (https=)
BR (1) BR112019012483A2 (https=)
CA (1) CA3045592A1 (https=)
CL (1) CL2019001745A1 (https=)
CO (1) CO2019006455A2 (https=)
CR (1) CR20190296A (https=)
CU (1) CU24644B1 (https=)
EA (1) EA201991526A1 (https=)
EC (1) ECSP19044625A (https=)
IL (2) IL300567A (https=)
JO (1) JOP20190155B1 (https=)
MA (1) MA47231A (https=)
MX (1) MX2019007582A (https=)
MY (1) MY193985A (https=)
PE (1) PE20191539A1 (https=)
PH (1) PH12019501330A1 (https=)
SA (1) SA519402188B1 (https=)
TW (2) TWI852077B (https=)
WO (1) WO2018116178A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102447350B1 (ko) * 2013-02-08 2022-09-23 노파르티스 아게 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
US10464969B2 (en) * 2016-05-05 2019-11-05 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
BR112018076306A2 (pt) * 2016-06-17 2019-03-26 Magenta Therapeutics, Inc. composições e métodos para a supressão de células cd117+
WO2019234694A2 (en) * 2018-06-07 2019-12-12 Magenta Therapeutics, Inc. Therapeutic methods using antibody drug conjugates (adcs)
TW202014209A (zh) * 2018-06-20 2020-04-16 瑞士商諾華公司 用於消融造血幹細胞之抗體藥物軛合物
AU2019312200B2 (en) * 2018-07-23 2024-11-14 Heidelberg Pharma Research Gmbh Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
CA3107383A1 (en) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
CN113330026A (zh) * 2018-10-23 2021-08-31 美真达治疗公司 Fc沉默的抗体药物缀合物(ADC)及其用途
EP3873532A1 (en) * 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
CN119684457A (zh) 2018-11-26 2025-03-25 四十七有限责任公司 针对c-kit的人源化抗体
WO2020121071A1 (en) * 2018-12-12 2020-06-18 Levim Biotech Llp Acylation process for preparation of n-substituted peptide
JP2022535527A (ja) * 2019-06-04 2022-08-09 マジェンタ セラピューティクス インコーポレイテッド 自己免疫疾患を治療するための方法および組成物
WO2021022678A1 (zh) * 2019-08-07 2021-02-11 烟台迈百瑞国际生物医药股份有限公司 一种抗体药物偶联物及其应用
CN116183899B (zh) * 2023-04-28 2023-06-30 天津市协和医药科技集团有限公司 一种吖啶酯标记抗体保存液的制备方法
TW202513593A (zh) * 2023-09-08 2025-04-01 大陸商信達生物製藥(蘇州)有限公司 半胱胺酸改造的抗體和免疫綴合物
WO2025080282A1 (en) * 2023-10-12 2025-04-17 Memorial Sloan-Kettering Cancer Center Combination therapy with clk/dyrk inhibitors and bcl2 inhibitors to treat leukemia

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
WO1992019244A2 (en) 1991-05-01 1992-11-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
DK0885002T3 (da) 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
KR101033196B1 (ko) 2002-02-14 2011-05-09 이뮤노메딕스, 인코오포레이티드 항-cd20 항체 및 그 융합 단백질 및 이들의 이용방법
WO2004002425A2 (en) 2002-06-28 2004-01-08 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
EP1606316A2 (en) 2003-03-24 2005-12-21 ZymoGenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之c-kit抗體
ES2882360T3 (es) * 2006-11-03 2021-12-01 Univ Leland Stanford Junior Inmunoempobrecimiento selectivo de un nicho de células madre endógenas para injerto
US8540517B2 (en) 2006-11-27 2013-09-24 Pharos Innovations, Llc Calculating a behavioral path based on a statistical profile
AU2010270979B2 (en) 2009-06-22 2015-04-23 Medimmune, Llc Engineered Fc regions for site-specific conjugation
US9540443B2 (en) * 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
AR086044A1 (es) 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
CN116574185A (zh) 2012-07-25 2023-08-11 塞尔德克斯医疗公司 抗kit抗体及其用途
KR102447350B1 (ko) 2013-02-08 2022-09-23 노파르티스 아게 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
NZ710929A (en) * 2013-03-15 2018-02-23 Novartis Ag Antibody drug conjugates
CA2940451A1 (en) * 2014-03-12 2015-09-17 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
CN106573956A (zh) * 2014-06-13 2017-04-19 诺华股份有限公司 澳瑞他汀衍生物及其缀合物
US10786578B2 (en) * 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
EP3215519A1 (en) * 2014-11-06 2017-09-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
HK1249534A1 (zh) * 2015-04-06 2018-11-02 哈佛大学校长及研究员协会 用於非清髓性预处理的组合物和方法
EP3310813A1 (en) * 2015-06-17 2018-04-25 Novartis AG Antibody drug conjugates
BR112018076306A2 (pt) 2016-06-17 2019-03-26 Magenta Therapeutics, Inc. composições e métodos para a supressão de células cd117+

Similar Documents

Publication Publication Date Title
JP2020504112A5 (https=)
JP7622017B2 (ja) 造血幹細胞を除去するための抗体薬物結合体
US20240424012A1 (en) Combinations and uses thereof
JP7526099B2 (ja) 抗cd38抗体の皮下投薬
JP6621447B2 (ja) 抗cd38抗体
RU2684468C2 (ru) Новые конъюгаты антител и их применения
TWI511978B (zh) 結合il-17a及il-17f之抗體分子
EP3678700B1 (en) Compounds for reducing the viscosity of biological formulations
RU2009149462A (ru) АНТИТЕЛА ПРОТИВ NRR Notch1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
RU2014116878A (ru) Цитотоксические пептиды и их конъюгаты антитело-лекарственное средство
JP2023542412A (ja) ピロロベンゾジアゼピン抗体複合体及びその使用
AU2012296905A1 (en) Combination therapy with an anti - CD19 antibody and a purine analog
JPWO2021147993A5 (https=)
CN119546345A (zh) 使用抗cd22抗体寡核苷酸缀合物治疗癌症的方法
JP2025130076A (ja) 抗cd38抗体及びその使用
JPWO2020257289A5 (https=)
RU2021100973A (ru) Конъюгаты антитела и лекарственного средства для разрушения гемопоэтических стволовых клеток
TWI853393B (zh) 人源化抗人類神經降壓素受體1抗體及其應用
EP4410836A1 (en) Anti-cd47 antibody for combined treatment of blood tumor
RU2810953C2 (ru) Подкожное дозирование антител к cd38
WO2025262130A1 (en) Antibody drug conjugate
JP2025529623A (ja) ヒト化抗ヒトニューロテンシン受容体1抗体及びそれらの使用
WO2024118106A1 (en) Cancer treatment with an ror1 antibody immunoconjugate and a btk inhibitor
TW202321308A (zh) 使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法
RU2022126092A (ru) Конъюгаты антитела и лекарственного средства для разрушения гемопоэтических стволовых клеток